<DOC>
	<DOCNO>NCT01834742</DOCNO>
	<brief_summary>This study investigate effect various modify low volume polyethylene glycol ( PEG ) 3350 ascorbic acid/ascorbate ( PEG+ASC ) -based gut cleanse solution stool output healthy subject . In addition , study ass compare safety tolerance modify PEG+ASC formulation follow oral administration safety profile MOVIPREPÂ® .</brief_summary>
	<brief_title>Pharmacodynamic Evaluation Stool Output Following Oral Administration Various Low Volume PEG3350-based Gut Cleansing Solutions Using Split Dose Intake Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Polyethylene glycol 3350</mesh_term>
	<criteria>1 . The subject 's write informed consent must obtain prior inclusion . 2 . Healthy subject age 18 45 year . 3 . Healthy subject need without history clinical significant gastrointestinal symptom clinical judgement without presence acute abdominal discomfort symptom . 4 . Females must surgically sterile , practice true sexual abstinence use acceptable form effective contraception throughout study follow list : contraceptive implant , injectables , oral contraceptive , intrauterine system ( IUS ) , intrauterine device ( IUDs ) , vasectomise partner barrier method ( condom occlusive cap ) spermicidal foam/gel/film/cream/suppository . Hormonal IUD method contraception must establish period 3 month prior dose change altered study . All female must negative pregnancy test screening checkin . 5 . Willing , able competent complete entire procedure comply study instruction . 1 . Use laxatives last 12 month colon motility alter drug last 6 month . 2 . Use prescription overthecounter ( OTC ) medication within 4 week prior first dose investigational drug ( exclude hormonal contraception , occasional use nonsteroidal antiinflammatory drug [ NSAID ] , acetaminophen metamizole ) . 3 . Donation loss 500 mL blood within 8 week prior first dose investigational drug . 4 . Any evidence history presence organic functional gastrointestinal condition ( e.g . chronic constipation , irritable bowel syndrome [ IBS ] , inflammatory bowel disease [ IBD ] ) . 5 . Exhibiting relevant abnormal gastrointestinal motility accord clinical judgement past . 6 . History presence clinically significant acute illness within 4 week prior first dose investigational drug base clinical judgement screen checkin evaluation . 7 . Known glucose6phosphatase dehydrogenase deficiency . 8 . Known phenylketonuria . 9 . History evidence clinical significant systemic cardiovascular , hepatic , pulmonal , neurological , metabolic and/or renal organ dysfunction . 10 . History clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) , know hypersensitivity polyethylene glycol and/or ascorbic acid . 11 . History evidence clinically relevant electrocardiogram ( ECG ) abnormalities hypertension . 12 . Evidence dehydration . 13 . Any evidence abnormal sodium potassium level clinically significant electrolyte disturbance . 14 . Females pregnant , positive pregnancy test screen and/or admission unit planning pregnancy . Females use reliable method birth control . 15 . Clinically relevant finding physical examination base Investigator 's judgement . 16 . Clinically relevant deviation laboratory parameter reference range screen checkin evaluation . 17 . Positive serology chronic viral hepatitis human immunodeficiency virus ( HIV ) screening . 18 . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen checkin evaluation . 19 . Subjects unwilling comply provision study protocol . 20 . Concurrent participation investigational drug study participation within 3 month study entry . 21 . Subject condition situation , Investigators opinion may put subject significant risk , may confound study result , may interfere significantly . 22 . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Moviprep</keyword>
	<keyword>PEG3350</keyword>
	<keyword>Laxative</keyword>
	<keyword>Stool Output</keyword>
</DOC>